14-20684198-G-C

Position:

• chr14-20684198-G-C

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_Strong BP6_Very_Strong BS1 BS2

The ENST00000336811.10(ANG):​c.-579G>C variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0254 in 152,384 control chromosomes in the GnomAD database, including 68 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

• Frequency:
  • Genomes: 𝑓 0.025 (68 hom., cov: 32)
  • Exomes 𝑓: 0.050 (0 hom.)
• Consequence: ANG ENST00000336811.10 5_prime_UTR
• Clinical Significance: Benign criteria provided, multiple submitters, no conflicts B:2
• Conservation: PhyloP100: -0.388

Genes affected

ANG (HGNC:483): (angiogenin) The protein encoded by this gene is a member of the RNase A superfamily though it has relatively weak ribonucleolytic activity. This protein is a potent mediator of new blood vessel formation and thus, in addition to the name RNase5, is commonly called angiogenin. This protein induces angiogenesis after binding to actin on the surface of endothelial cells. This protein also accumulates at the nucleolus where it stimulates ribosomal transcription. Under stress conditions this protein translocates to the cytosol where it hydrolyzes cellular tRNAs and influences protein synthesis. A signal peptide is cleaved from the precursor protein to produce a mature protein which contains a nuclear localization signal, a cell binding motif, and a catalytic domain. This protein has been shown to be both neurotrophic and neuroprotective and the mature protein has antimicrobial activity against some bacteria and fungi, including S. pneumoniae and C. albicans. Due to its effect on rRNA production and angiogenesis this gene plays important roles in cell growth and tumor progression. Mutations in this gene are associated with progression of amyotrophic lateral sclerosis (ALS). This gene and the neighboring RNase4 gene share promoters and 5' exons though each gene then splices to a distinct 3' exon containing the complete coding region of each gene. Alternative splicing results in multiple transcript variants encoding the same protein. [provided by RefSeq, Jul 2020]

ACMG classification

Verdict is Benign. Variant got -20 ACMG points.

• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.56).
• BP6: Variant 14-20684198-G-C is Benign according to our data. Variant chr14-20684198-G-C is described in ClinVar as [Benign]. Clinvar id is 312760.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
• BS1: Variant frequency is greater than expected in population sas. gnomad4 allele frequency = 0.0254 (3866/152344) while in subpopulation SAS AF= 0.0422 (204/4832). AF 95% confidence interval is 0.0375. There are 68 homozygotes in gnomad4. There are 2040 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
• BS2: High AC in GnomAd4 at 3866 AD gene.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
ANG	NM_001145.4	c.-579G>C		5_prime_UTR_variant	1/2		NP_001136.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
ANG	ENST00000336811.10	c.-579G>C		5_prime_UTR_variant	1/2	1		ENSP00000336762	P1

Frequencies

GnomAD3 genomes AF: 0.0254 AC: 3867 AN: 152226 Hom.: 68 Cov.: 32

Gnomad AFR AF: 0.00605

Gnomad AMI AF: 0.0121

Gnomad AMR AF: 0.0208

Gnomad ASJ AF: 0.0150

Gnomad EAS AF: 0.00154

Gnomad SAS AF: 0.0426

Gnomad FIN AF: 0.0676

Gnomad MID AF: 0.0348

Gnomad NFE AF: 0.0328

Gnomad OTH AF: 0.0287

GnomAD4 exome AF: 0.0500 AC: 2 AN: 40 Hom.: 0 Cov.: 0 AF XY: 0.0667 AC XY: 2 AN XY: 30

Gnomad4 FIN exome AF: 0.0833

Gnomad4 NFE exome AF: 0.00

Gnomad4 OTH exome AF: 0.100

GnomAD4 genome AF: 0.0254 AC: 3866 AN: 152344 Hom.: 68 Cov.: 32 AF XY: 0.0274 AC XY: 2040 AN XY: 74494

Gnomad4 AFR AF: 0.00606

Gnomad4 AMR AF: 0.0208

Gnomad4 ASJ AF: 0.0150

Gnomad4 EAS AF: 0.00154

Gnomad4 SAS AF: 0.0422

Gnomad4 FIN AF: 0.0676

Gnomad4 NFE AF: 0.0328

Gnomad4 OTH AF: 0.0284

Alfa AF: 0.0174 Hom.: 9

Bravo AF: 0.0199

Asia WGS AF: 0.0230 AC: 80 AN: 3478

ClinVar

Significance: Benign

Submissions summary: Benign:2

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Amyotrophic lateral sclerosis type 9 Benign:1

Benign, criteria provided, single submitter

clinical testing

Illumina Laboratory Services, Illumina

Jan 12, 2018

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:1

Benign, criteria provided, single submitter

not provided

Breakthrough Genomics, Breakthrough Genomics

-

- -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.56
CADD	Benign	0.22
DANN	Benign	0.54

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs117466368; hg19: chr14-21152357;